Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.
Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center
Advertisement
Articles by Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Role of Combination I/O in Advanced Endometrial Cancer (EC)April 14th 2021
Advertisement
Advertisement
Trending on OncLive
1
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
2
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer
3
CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma
4
Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma
5